American Journal of Pharmacological Sciences
ISSN (Print): 2327-6711 ISSN (Online): 2327-672X Website: Editor-in-chief: Srinivas NAMMI
Open Access
Journal Browser
American Journal of Pharmacological Sciences. 2013, 1(2), 22-28
DOI: 10.12691/ajps-1-2-2
Open AccessArticle

Effects of Amlodipine and Hydrochlorothiazide Combination Therapy on Lipid Profiles in Hypertensive Nigerians

G.B.S. Iyalomhe, , E.K.I. Omogbai and O.O.B. Iyalomhe

Pub. Date: April 29, 2013

Cite this paper:
G.B.S. Iyalomhe, E.K.I. Omogbai and O.O.B. Iyalomhe. Effects of Amlodipine and Hydrochlorothiazide Combination Therapy on Lipid Profiles in Hypertensive Nigerians. American Journal of Pharmacological Sciences. 2013; 1(2):22-28. doi: 10.12691/ajps-1-2-2


There is paucity of information regarding the effects of combination therapy with amlodipine and hydrochlorothiazide on lipid profiles in hypertensive Nigerians. Therefore, to evaluate whether this combination therapy would ameliorate or aggravate the known metabolic adversity of hydrochlorothiazide on lipid parameters, 90 male and female Nigerians aged 31-86 years with newly diagnosed uncomplicated essential hypertension (blood pressure > 160/90 ≤ 180/120mmHg) were enrolled into a randomised 48-week study. Treatment was initiated in the patients, who were 30 each in amlodipine, hydrochlorothiazide and amlodipine-hydrochlorothiazide groups, with amlodipine 5mg, hydrochlorothiazide 25mg and amlodipine 5mg + hydrochlorothiazide 25mg, respectively. Body mass index, blood pressure and lipid profiles were evaluated at baseline as well as at the end of weeks 1, 3, 6, 12, 24, 36 and 48. The 3 regimens significantly (p<0.05) reduced blood pressure. At the end of week 48, mean male/female % significant decrease or increase in lipid parameters in amlodipine, hydrochlorothiazide and amlodipine-hydrochlorothiazide groups were, respectively: -4.3/-1.5, 2.8/3.7 and 2.6/2.5, p<0.0001 for total cholesterol; -7.2/-2.6, 5.3/5.6 and 6.6/6.2, p<0.0001 for triglyceride; 16.5/19.6, -12.0/-8.6 and -7.8/-8.4, p<0.0001 for high density lipoprotein cholesterol; -4.6/-3.0, 5.6/11.7 and 4.5/8.0, p<0.0001 for low density lipoprotein cholesterol. This study demonstrates that beyond reducing blood pressure, amlodipine and hydrochlorothiazide combination therapy has varied effects on lipid panel and it also suggests that, with regard to cardiovascular risk profile, it may be preferable to initiate treatment with a regimen of amlodipine to which hydrochlorothiazide is subsequently added, instead of a regimen of hydrochlorothiazide to which amlodipine is later added or a regimen of ab initio amlodipine-hydrochlorothiazide combination therapy.

Amlodipine hydrochlorothiazide antihypertensive combination therapy lipid profiles nigerians

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.C. and He, J., “Global burden of hypertension: analysis of worldwide data,” Lancet, 365 (9455), 217-223, Jan. 2005.
[2]  Gunaranthne, A., Patel, J.V., Potluri, R., Gill, P.S., Hughes E.A. and Lip, G.Y.H., “Secular trends in the cardiovascular risk profile and mortality of stroke admissions in an inner city, multiethnic population in the United Kingdom (1997-2005),” Journal of Human Hypertension, 22 (1), 18-23, Jan. 2008.
[3]  Akinkugbe, O.O., “Current epidemiology of hypertension in Nigeria”. Archives of Ibadan Medicine, 1, 3-5, 2003.
[4]  Imam, I. and Olorunfemi, G., “The profile of stroke in Nigeria’s federal capital territory,” Tropical Doctor, 32 (4), 209-212, Oct. 2002.
[5]  Ike, S.O., “Prevalence of hypertension and its complications among medical admissions at the University of Nigeria Teaching Hospital, Enugu (Study 2),” Nigerian Journal of Medicine, 18 (1), 68-72, Jan. 2009.
[6]  Hokanson, J.E. and Austin, M.A., “Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein: a meta-analysis of population based prospective studies,” Journal of Cardiovascular Risk, 3 (2), 213-219, Apr. 1996.
[7]  Halperin, R.O., Sesso, H.D., Ma, J., Buring, J.E., Stampfer, M.J. and Gaziano, J.M., “Dyslipidemia and the risk of incident hypertension in men,” Hypertension, 47 (1), 45-50, Jan. 2006.
[8]  NCEP, ”Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report,” Circulation, 106 (25), 3143-3421, 2002.
[9]  Sever, P.S., Poulter, N.R. and Elliot, W.J., “Blood pressure reduction is not the only determinant of outcome,” Circulation, 113, 2754-2772, 2006.
[10]  Collins, R., Armitage, J., Parish, S., Sleight, P., Peto R., Heart Protection Study Collaborative Group, “Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions,” Lancet, 363 (9411), 757-767, Mar. 2004.
[11]  Bronas, U.G. and Leon A.S., “Lifestyle modifications for its prevention and management,” American Journal of Lifestyle Medicine, 3 (6), 425-439, Nov. 2009.
[12]  Gradman, A.H. and Acevedo, C., “Evolving strategies for the use of combination therapy in hypertension”. Current Hypertension Reports, 4 (5), 343-349, Oct. 2002.
[13]  Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., et al., “The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report,” The Journal of the American Medical Association, 289 (19), 2560-2572, May 2003.
[14]  Williams, B., Poulter, N.R., Brown, M.J., Davis, M., Mclnnes, G.T., et al., “British hypertension society guidelines for hypertension management 2004 (BHS-IV): Summary,” British Medical Journal, 328 (7440), 634-640, Mar. 2004.
[15]  Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., et al., “Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” Journal of Hypertension, 25 (6), 1105-1187, Jun. 2007.
[16]  Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., et al., “Reappraisal of European guidelines on hypertension management: A European society of hypertension task force document,” Journal of Hypertension, 27 (11), 2121-2158, Nov. 2009.
[17]  Wong, M.C.S., Jiang, J.Y., Ali, M.K., Fung, H., Griffiths, S., and Mercer, S.W., “Antihypertensive drug class and dyslipidemia: risk association among chinese patients with uncomplicated hypertension,” Journal of Human Hypertension, 22 (9), 648-651, Sep. 2008.
[18]  Koh, K.K., Quon, M.J., Han, S.H., Lee, Y., Kim, S.J., Koh, Y. and Shin, E.K., “Distinct vascular and metabolic effects of different classes of antihypertensive drugs,” International Journal of Cardiology, 140 (1), 73-81, Apr. 2010.
[19]  Leonetti, G., “Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: A double blind, prospective, randomized clinical trial,” Current Medical Research and Opinion, 21 (6), 951-958, Jun. 2005.
[20]  Nandeesha, H., Pavithran, P. and Madanmohan, T., “Effect of antihypertensive therapy on serum lipids in newly diagnosed essential hypertensive men,” Angiology, 60 (2), 217-220, Apr. 2009
[21]  Christogiannis, L.G., Kostapanos, M.S., Tellis, C.C., Millionis, H.J., Tselepis, A.D. and Elisaf, M.S., “Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension,” Journal of Human Hypertension, 27 (1), 44-50, Jan. 2013.
[22]  Tejada, T., Fornoni, A., Lenz, O. and Materson, B.J., “Combination therapy with renin-angiotensin system blockers: Will amlodipine replace hydrochlorothiazide?” Current Hypertension Reports, 9 (4), 284-290, Aug. 2007.
[23]  Messerli, F.H., Bangalore, S. and Julius, S., “Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension,” Circulation, 117 (20), 2706-2715, May 2008.
[24]  Ellison, D.H. and Loffing, J., “Thiazide effects and adverse effects: Insights from molecular genetics,” Hypertension, 54 (2), 196-202, Aug. 2009.
[25]  Grossman, E., Verdecchia, P., Shamiss, A., Angeli F., and Reboldi, G., “Diuretic treatment of hypertension,” Diabetes Care, 34 (Suppl 2), S313-S319, May 2011.
[26]  Ma, L., Wang, W., Zhao, Y., Zhang, Y., Deng, Q., et al., “Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: A 96-week efficacy and safety study,” American Journal of Cardiovascular Drugs, 12 (2), 137-142, Apr. 2012.
[27]  Sareli, P., Radevski, I.V., Valtchanova, Z.P., Libhaber, E., Candy, G.P., et al., “Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: Results of a randomized trial in Johannesburg, South Africa,” Archives of Internal Medicine, 161 (7), 965-971, Apr. 2001.
[28]  Brewster, L.M., van Montfrans, G.A. and Kleijnen, J., “Systematic review: Antihypertensive drug therapy in black patients,” Annals of Internal Medicine, 141 (8), 614-627, Oct. 2004.
[29]  Isah, A.O., Obasohan, A.O. and Okpako, L.O., “Open evaluation of amlodipine in the monotherapeutic treatment of mild to moderate hypertension in Nigerian patients,” Current Therapeutic Research, 52, 812-818, 1992.
[30]  Wright, J.T., Dunn, J.K., Cutler, J.A., Davis, B.R., Cushman, W.C., et al., “Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine and lisinopril,” The Journal of the American Medical Association, 293 (13), 1595-1608, Apr. 2005.
[31]  Salako, B.L., Kadiri, S., Walker, O. and Fehintola, F.A., “Evaluation of lacidipine (a calcium blocker) in the treatment of hypertension in black African people: A double-blind comparison with hydrochlorothiazide,” African Journal of Medicine and Medical Science, 27 (1-2), 73-75, Mar. 1998.
[32]  Iyalomhe, G.B.S., Omobgai, E.K.I. and Ozolua, R.I., “Antihypertensive and some biochemical effects of hydrochlorothiazide and furosemide in some Nigerians,” Journal of Medical Sciences, 7 (6), 977-983, Aug. 2007.
[33]  Pickering, T.G., Hall, J.E., Appel, L.J., Falkner, B.E., Graves, J., et al., “Recommendations for blood pressure measurement in humans and experimental animals Part 1: blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research,” Hypertension, 45 (1), 142-161, Jan. 2005.
[34]  Pesce, A.J. and L.A. Kaplan, 1987. Methods in Clinical Chemistry. Mosby Company, St. Louis, USA, ISBN-13: 9780801638299, Pages: 1366.
[35]  Friedewald, W.T., Levy, R.I. and Fredrickson, D.S., “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrafuge,” Clinical Chemistry, 18 (6), 499-502, Jun. 1972.
[36]  Statistical Analysis System, “The SAS for Windows,” Release 8.20, SAS Institute, Carry, NC., USA, 2004.
[37]  Iyalomhe, G.B.S. and Iyalomhe, S.I., “Hypertension-related knowledge, attitudes and life-style practices among hypertensive patients in a sub-urban Nigerian community,” Journal of Public Health amd Epidemiology, 2 (4), 71-77, Jul. 2010.
[38]  Mason, R.P., Marche, P. and Hintze, T.H., “Novel vascular biology of third-generation L-type calcium channel antagonists: Ancillary actions of amlodipine,” Arteriosclerosis, Thrombosis and Vascular Biology, 23 (12), 2155-2163, Dec. 2003.
[39]  Toba, H., Nakagawa, Y., Miki, S., Shimizu, T., Yoshimura, A., et al., “Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augumentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methylester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure- lowering effects of amlodipine and manidipine,” Hypertension Research, 28, 689-700, 2005.
[40]  Mayer, B., “Translocation of endothelial nitric oxide synthase: Another feat of amlodipine, a cardiovascular jack-of-all-trades,” Cardiovascular Research, 71 (3), 411-413, Aug. 2006.
[41]  Fournier, A., Messerli, F.H., Achard, J.M. and Fernandez, L., “Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials,” Journal of the American College of Cardiology, 43 (8), 1343-1347, Apr. 2004.
[42]  Brook, R.D., “Mechanism of differential effects of antihypertensive agents on serum lipids,” Current Hypertension Reports, 2 (4), 370-377, Aug. 2000.
[43]  Hernandez, R.H., Armas-Hernandez, M.J., Velasco, M., Israili, Z.H. and Armas-Padilla, M.C., “Calcium antagonists and atherosclerosis protection in hypertension,” American Journal of Therapeutics, 10 (6), 409-414, Nov. 2003
[44]  Lakshman, M.R., Reda, D.J., Materson, B.J., Cushman, W.C. and Freis, E.D., “Diuretics and β-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension,” Archives of Internal Medicine, 159, 551-558, 1999.
[45]  Dahlof, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, D.G., et al., “Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial,” Lancet, 366 (9489), 895-906, Sep. 2005.
[46]  Jamerson, K., Weber, M.A., Bakris, G.L., Dahlof, B., Pitt, B., et al., “Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients,” The New England Journal of Medicine, 359 (23), 2417-2428, Dec. 2008.